Even the government has plumbing problems
Executive Summary
"As soon as they put it in front of me to sign," Office of New Drugs Director John Jenkins says, he will sign a memorandum of agreement setting out the duties of OND and Office of Safety and Epidemiology staff in reviewing safety issues for new drugs. A scheduled June 16 signing of the memo by Jenkins and OSE Director Gerald Dal Pan was delayed when a broken water main closed some FDA offices. Personnel in the two offices already are operating under the new procedures, the two assured those attending a June 26 town hall meeting during the Drug Information Association meeting in Boston. If staff cannot resolve their differences, the agreement calls for passing decisions up to the two office directors and then to CDER Director Janet Woodcock, if necessary. The latter will be a "rare occurrence," Jenkins and Dal Pan insist
You may also be interested in...
FDA Drug Review, Surveillance Offices Agree To Share Safety Authority
FDA's drug review and drug safety offices have set aside their differences and laid out an agreement that more equally divides regulatory authority on issues related to drug safety
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.